[Therapeutical effectiveness of interferon alpha in a child with craniofacial giant hemangioma: case report].
Hemangiomas are the most common benign tumors of infancy. Capillary hemangioma generally is presented as a spot or well-defined purple lesion. The diagnosis of these tumors is based on physical examination. Giant hemangioma is a rare and extensive variation of capillary hemangioma, that generally occurs in newborns and suckling infants. There are several therapeutical modalities, as the intralesional injection of steroids, laser therapy, intralesional injection of sclerosing solutions, surgery, radiotherapy and embolization. New therapeutical modalities have been developed, with the objective of getting better results and to make possible the treatment of the lesions of difficult surgical access or refractory cases to the used therapeutical modalities. The best results have been observed with interferon-alpha. This is a case of a patient with three months of age, that presented since birth, a purplish tumor in the superior eyelid of the right eye, plain and purplish cutaneous lesions in the temporal and parietal right region. On computed tomography of the skull, an orbital expansive vascularized process with intracranial extension could be observed. Systemic therapy with steroids was the initial treatment, during forty days, with gradual reduction for four weeks. With the practically unchanged clinical findings, the treatment with interferon-alpha was indicated, in the dose of subcutaneous 3.000.000 U/m(2), three times a week. After 9 months of treatment, a small residual orbital lesion was observed. In this case, interferon-alpha is presented as a good option for the treatment of craniofacial giant hemangioma.
Fonseca Junior
Nilson Lopes da
NL
Faculdade de Medicina, ABC, Santo André, SP, Brasil. lopesdafonseca@uol.com.br
Cha
Sung Bok
SB
Cartum
Jairo
J
Rehder
José Ricardo Carvalho Lima
JR
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019465:Craniofacial Abnormalities / Q000188:drug therapy*; D005153:Facial Neoplasms / Q000188:drug therapy*; D005260:Female; D006392:Hemangioma, Cavernous / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D016898:Interferon-alpha / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D016898:Interferon-alpha